Maxim Group Downgrades BioLineRx (BLRX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession
August 11, 2016 11:46 AM EDTRoth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of a new CEO, as announced early Thursday.
Analyst Joseph Pantginis commented, The company has several important catalysts slated by year-end, which should be able to address the recent... More
BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones
August 11, 2016 7:19 AM EDTBioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07).
Expected upcoming significant milestones for remainder of 2016:
Initiation of Phase 2a study in pancreatic cancer, under immuno-oncology collaboration with Merck, following expected regulatory approval in Q3... More